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Background: Increasing evidence suggests that forkhead box A1 (FOXA1) is frequently dysregulated in many types
of human cancers. However, the exact function and mechanism of FOXA1 in human endometrial cancer (EC)
remains unclear.
Methods: FOXA1 expression, androgen receptor (AR) expression, and the relationships of these two markers with
clinicopathological factors were determined by immunohistochemistry analysis. FOXA1 and AR were up-regulated
by transient transfection with plasmids, and were down-regulated by transfection with siRNA or short hairpin RNA
(shRNA). The effects of FOXA1 depletion and FOXA1 overexpression on AR-mediated transcription as well as Notch
pathway and their impact on EC cell proliferation were examined by qRT-PCR, western blotting, co-immunoprecipitation,
ChIP-PCR, MTT, colony-formation, and xenograft tumor–formation assays.
Results: We found that the expression of FOXA1 and AR in ECs was significantly higher than that in a typical
hyperplasia and normal tissues. FOXA1 expression was significantly correlated with AR expression in clinical
tissues. High FOXA1 levels positively correlated with pathological grade and depth of myometrial invasion in EC.
High AR levels also positively correlated with pathological grade in EC. Moreover, the expression of XBP1, MYC,
ZBTB16, and UHRF1, which are downstream targets of AR, was promoted by FOXA1 up-regulation or inhibited by
FOXA1 down-regulation. Co-immunoprecipitation showed that FOXA1 interacted with AR in EC cells. ChIP-PCR
assays showed that FOXA1 and AR could directly bind to the promoter and enhancer regions upstream of MYC.
Mechanistic investigation revealed that over-expression of Notch1 and Hes1 proteins by FOXA1 could be reversed
by AR depletion. In addition, we showed that down-regulation of AR attenuated FOXA1-up-regulated cell proliferation.
However, AR didn’t influence the promotion effect of FOXA1 on cell migration and invasion. In vivo xenograft model,
FOXA1 knockdown reduced the rate of tumor growth.
Conclusions: These results suggest that FOXA1 promotes cell proliferation by AR and activates Notch pathway. It
indicated that FOXA1 and AR may serve as potential gene therapy in EC.
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Endometrial cancer (EC) is one of the most common
gynecologic malignancies. The incidence of EC has
markedly increased in recent years. EC is broadly classi-
fied into two groups [1]; type I ECs are linked to estro-
gen excess, hormone-receptor positivity, and favorable
prognoses, whereas type II, primarily serous tumors, are
more common in older women and have poorer outcomes
[2]. Primary treatment, including surgery and radiation,
cannot provide sufficient tumor control, especially in
high-grade, undifferentiated tumors with deep muscle
infiltration. Endocrine treatment, including medroxypro-
gesterone acetate or tamoxifen, is sometimes useful to im-
prove the outcome. However, patients with type II EC and
even some patients with type I EC are refractory to trad-
itional endocrine treatment [3]. Thus, a new treatment is
needed to achieve a better response.
Several studies have shown that the majority of ECs
also express another hormone receptor, androgen recep-
tor (AR) [4,5]. The results of immunohistochemical ana-
lysis indicate that, compared with endometrial glandular
epithelial cells in normal cycling endometrium, more
epithelial cells express AR in ECs [4]. Moreover, in fe-
male mice, in contrast to AR−/− uteri, AR+/+ uteri have
uterine hypertrophy and endometrial growth [6]. It thus
is very important to examine the possible actions and
metabolism mediated by AR in human EC.
Forkhead box A1 (FOXA1) is a transcription factor
that belongs to the forkhead family consisting of the
winged-helix DNA-binding domain and the N-terminal
and C-terminal transcriptional domains. FOXA1 is ex-
pressed in various organs, including breast, liver, pan-
creas, and prostate, and can influence the expression of
a large number of genes associated with metabolic pro-
cesses, regulation of signaling, and the cell cycle [7,8].
FOXA1 has been identified as a “pioneer factor” that
binds to chromatin-packaged DNA and opens the chro-
matin for binding of additional transcription factors, in-
cluding AR [9]. FOXA1 also binds directly to AR and
regulates transcription of prostate-specific genes in pros-
tate cancer [10]. Recent global gene expression studies
of prostate cancer and triple-negative breast cancer have
shown that high FOXA1 expression, which correlates
positively with AR level, promotes tumor proliferation
[11,12]. Thus, FOXA1 expression is considered a pre-
dictor of poor survival in prostate cancer and triple-
negative breast cancer. However, the interaction between
FOXA1 and AR in EC remains unclear.
An aberrant Notch pathway has been documented in
various cancer types and has been associated with tumori-
genesis [13-15]. The Notch pathway is initiated by ligand
binding, which is followed by intramembranous proteo-
lytic cleavage of the Notch1 receptor to release an active
form of the Notch intracellular domain (NICD). TheNICD subsequently translocates to the nucleus and acts
as a transcriptional activator to enhance the expression
of target genes such as Hairy-enhancer of split1 (Hes1)
[16]. Abnormal activation of the Notch pathway pro-
motes proliferation in a variety of cancer cell types,
including EC [15,17].
In the present study, we investigated the dependency
of AR on FOXA1 expression in tissue paraffin sections,
in multiple cellular contexts, and on tumor-bearing nude
mice. Here we show, for the first time, that FOXA1 acti-
vates the Notch pathway through AR and that AR is re-
quired for FOXA1-enhanced cell proliferation in EC.
Methods
Patients and tissues
A total of 57 normal endometrial samples, 11 atypical
hyperplasias, and 76 EC specimens obtained from Chin-
ese female patients who underwent surgical treatment
from 2011 to 2013 at the Shanghai Jiao Tong University
Affiliated International Peace Maternity & Child Health
Hospital (Shanghai, China) were available for examin-
ation in this study. Tissues were embedded in paraffin.
Two independent pathologists verified the histological
diagnosis of all collected tissues. No patient had received
neoadjuvant therapy or endocrine therapy before the sur-
gery. The clinicopathological characteristics of EC patients
are presented in Table 1. The samples of EC, atypical hy-
perplasias and normal endometrial tissues were collected
after written informed consent from the patients. The
Human Investigation Ethical Committee of the Inter-
national Peace Maternity & Child Health Hospital Affili-
ated Shanghai Jiao Tong University approved this study.
Immunohistochemical staining
Staining was performed on paraffin-embedded speci-
mens using primary antibodies as follows: anti-FOXA1
(1:200; Abcam, Cambridge, MA, USA) and anti-AR
(1:50; Abcam). The percentage of positively stained cells
was rated as follows: 0 point = 0%, 1 point = 1% to 25%,
2 points = 26% to 50%, 3 points = 51% to 75%, and 4
points = greater than 75%. The staining intensity was rated
in the following manner: 0 points = negative staining, 1
point = weak intensity, 2 points =moderate intensity, and
3 points = strong intensity. Then, immunoreactivity scores
for each case were obtained by multiplying the values
of the two parameters described above. The average score
for all of five random fields at 200× magnification was
used as the histological score (HS). Tumors were catego-
rized into two groups based on the HS: low-expression
group (HS = 0–5) and high-expression group (HS = 6–12).
Cell culture and experimental setup
The human endometrial cell lines AN3CA, RL95-2, and
HEC-1B were obtained from the Chinese Academy of
Table 1 The relationship between protein expression and
clinicopathological features in EC
Parameter n FOXA1 p AR p
High Low High Low
Age
≤55 31 21 10 0.916 19 12 0.493
>55 45 31 14 31 14
FIGO stage
I–II 64 41 23 0.059 41 23 0.464
III–IV 12 11 2 9 3
Pathological type
Adenocarcinoma 63 47 16 0.469 41 22 0.774
Papillary serous carcinoma 13 10 3 9 4
Histological grade
G1 35 19 16 0.038 18 17 0.040
G2 22 17 5 18 4
G3 6 6 0 5 1
Lymph node metastasis
Positive 7 6 1 0.271 5 2 0.86
Negative 66 43 23 45 21
Depth of myometrial
invasion
≤1/2 47 28 19 0.035 29 18 0.339
>1/2 29 24 5 21 8
ERα expression
Positive 61 43 18 0.434 41 20 0.598
Negative 15 9 6 9 6
P53 expression
Positive 20 14 6 0.86 15 5 0.312
Negative 56 38 18 35 21
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These three cell lines were grown in Dulbecco’s modified
Eagle’s medium (DMEM)/F12 (HyClone, Waltham, MA,
USA) supplemented with 10% fetal bovine serum (Gibco,
Carlsbad, CA, USA) in a humidified atmosphere of 5%
CO2 at 37°C. The human endometrial cell line MFE-296
was purchased from Sigma (St. Louis, MO, USA). The
MFE-296 cell line was grown in high-glucose DMEM
(4.5 g/L glucose) (HyClone) supplemented with 10%
fetal bovine serum in a humidified atmosphere of 5%
CO2 at 37°C.
To investigate the impact of FOXA1 on the AR-
mediated transcription, the AR pathway agonist 5α-
dihydrotestosterone (DHT) (Dr. Ehrenstorfer, Augsburg,
Germany) and the AR pathway blocker flutamide (Sigma)
were purchased and dissolved in 100% ethanol for storage.
In this study they were diluted with phenol red–free
DMEM/F12 (Gibco) immediately before each experi-
ment, with the final concentration of ethanol at 0.1%.DHT was added into the cell culture media at concentra-
tions of 10−9 to 10−7 M for different periods (0–48 h). To
block the activation of AR-mediated transcription, fluta-
mide (10−6 M) was added into the media 30 min before
DHT. Vehicle contained 0.1% absolute ethanol/phenol
red–free DMEM/F12.
Stable transfection
To stably knock down endogenous FOXA1 expression,
MFE-296 cells were grown to 30% confluency in 6-well cul-
ture plates and then infected with lentivirus carrying an
shRNA targeting FOXA1 (shFOXA1) or a negative control
vector (NC; LV3-pGLV-h1-GFP-puro vector, D03004; Gen-
ePharma, Shanghai, China) at a multiplicity of infection of
70 in the presence of polybrene (8 μg/mL). After 48 h of
infection at 37°C, the medium was replaced with fresh
medium and incubated further for 72 h before analysis
using quantitative RT-PCR (qRT-PCR) and western blotting




The plasmid PWP1/GFP/Neo-AR containing transfection-
ready AR cDNA (exAR) and its negative control PWP1/
GFP/Neo were gifts from Doctor Yuyang Zhao at Shanghai
First People’s Hospital. MFE-296 cells stably transfected
with shFOXA1 or NC were transiently cotransfected
with PWP1/GFP/Neo-AR (exAR) or its negative control
(NC). The plasmid pCMV/3FLAG/Neo-FOXA1 con-
taining transfection-ready FOXA1 cDNA (exFOXA1)
(GenBank: BC033890) and a pure pCMV/3FLAG/Neo
(NC) were purchased from Genechem (Product code:
GOSE33403; Shanghai, China). AN3CA cells were transi-
ently transfected with exFOXA1 or NC or cotransfected
with a siRNA targeting AR (siAR) (Genephama Biotech,
Shanghai, China) or its negative control (NC) in Opti-
MEM (Invitrogen, Carlsbad, CA, USA) using Lipo2000
(Invitrogen). The siRNA targeting FOXA1 (siFOXA1) and
its negative control (NC) were purchased from Genephama
Biotech (Shanghai, China). AN3CA cells were transiently
transfected with exAR or NC or cotransfected with siF
OXA1 or NC in Opti-MEM (Invitrogen) using Lipo2000
(Invitrogen). The transfection solution was removed from
the cells and replaced with standard medium after 8 h. The
sequences of the siRNA oligos used were: siAR: sense: 5′-
AUGUCAACUCCAGGAUGCUTT-3′, antisense: 5′-AGC




Total RNA was extracted from cultured cells by Trizol
Reagent (Invitrogen). RNA was converted to cDNA with
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China), and the cDNA was analyzed by real-time PCR
using SYBR Premix Ex Taq (TaKaRa) in an Eppendorf
Mastercycler® realplex. Each sample was assayed in trip-
licate in each of three independent experiments. All
values are expressed as mean ± standard deviation. The
following primers were used: FOXA1: sense: 5′-AG
GTGTGTATTCCAGACCCG-3′, antisense: 5′-TTGAC
GGTTTGGTTTGTGTG-3′; AR: sense: 5′-CCTGGCT
TCCGCAACTTACAC-3′, antisense: 3′-GGACTTGTG
CATGCGGTACTCA-5′; MYC: sense: 5′-AAAGGCCC
CCAAGGTAGTTA-3′, antisense: 5′-TTTCCGCAA
CAAGTCCTCTT-3′; XBP1: sense: 5′-CCTTGTAGTT
GAGAACCAGG-3′, antisense: 5′-GGGGCTTGGTAT
ATATGTGG-3′; UHRF1: sense: 5′-AAGGTGGAGCC
CTACAGTCTC-3′, antisense: 5′-CACTTTACTCAG




Total protein was extracted using a RIPA kit (Beyotime,
Shanghai, China) containing a 1% dilution of the prote-
ase inhibitor PMSF (Beyotime). Protein concentrations
were determined by the enhanced BCA Protein Assay
kit (Beyotime). Equal amounts of protein in each lane
were separated by 8% SDS-PAGE and transferred to a
PVDF membrane (Millipore, Billerica, MA, USA). After
blocking the membrane in blocking buffer (5% milk
powder in 20 mM Tris–HCl pH 7.5, 500 mM NaCl,
0.1% (v/v) Tween 20), the membrane was incubated with
primary antibodies against FOXA1 (1:1000; Abcam), AR
(1:2000; Cell Signaling Technology, Danvers, MA, USA),
Notch1 (1:2000; Epitomics, Burlingame, CA, USA), Hes1
(1:2000; Epitomics), and β-actin (1:2000, Cell Signaling
Technology) at 4°C overnight. Peroxidase-linked second-
ary anti-rabbit or anti-mouse antibodies were used to
detect the bound primary antibodies.
Co-immunoprecipitation
Total protein was extracted from cells treated or not
treated with 10−7 M DHT for 24 h (described in the Cell
culture and experimental setup section). After protein
quantification, 500 μg of each cell lysate was added to
10 μl of anti-FOXA1 (Epitomics) and shaken at 4°C
overnight, then added to 30 μl of Protein A + G Agarose
(Beyotime), shaken at 4°C for 4 h, centrifuged at 2500 × g
for 5 min, and washed with a RIPA kit (Beyotime) to col-
lect the immunoprecipitate-bound agarose beads. Each
immunoprecipitate was denatured with 20 μl of 1× SDS-
PAGE loading buffer at 100°C for 5 min. Each supernatant
was subjected to SDS-PAGE (8% acrylamide). It is import-
ant to note that FOXA1 (51 kDa) is close in size to IgG
(55 kDa). To avoid detecting IgG protein left from theimmunoprecipitation process and FOXA1 protein from
the same species in the western blot at the same time, we
used anti-FOXA1 from mouse in western blotting,
whereas anti-FOXA1 from rabbit was used for immuno-
precipitation. Primary antibodies against AR (1:2000) and
FOXA1 (1:500; Santa Cruz Biotechnology, Dallas, TX,
USA) were used for western blotting. Other steps were as
described in the Western blotting section.
Chromatin immunoprecipitation (ChIP)-PCR
Chromatin immunoprecipitation (ChIP) assays were per-
formed as previously described [18] using anti-FOXA1
antibody (ab23738, Abcam), anti-AR antibody (sc-7305,
Santa Cruz Biotechnology). FOXA1-AR overlapping bind-
ing sites were identified by Chip-seq as previously depicted
[19] and by qRT-PCR using SYBR Premix Ex Taq (Takara).
Enrichment was calculated using the comparative Ct
method, and was analyzed for specificity, linearity range,
and efficiency in order to accurately evaluate the occu-
pancy (percentage of immunoprecipitation/input). IgG
was used as negative control. The primers used in-
cluded: MYC pro: sense: 5′-CCCCCGAATTGTTTT
CTCTT-3′, antisense: 5′-TCTCATCCTTGGTCCCTC
AC-3′; MYC enh-1: sense: 5′-AGACAGAGGCAGG
GTGGAG-3′, antisense: 3′-CCCAGGTAAACAGCCA
ATGT-5′; MYC enh-2a: sense: 5′-CCGTTCCGTGTC
TAACCACT-3′, antisense: 5′-ATGAAACTCGGGGAG
TGTTG-3′; MYC enh-2b: sense: 5′-AGCGTTCTCTT
TGCCAGAAA-3′, antisense: 3′-GGCAAAGCTTCA




Cells (3 × 103 cells/well) were plated in 96-well plates.
Then, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT, 5 mg/ml; Sigma) was added
to each well and subsequently incubated at 37°C for 4 h.
The absorbance at 490 nm was then measured using a
microplate reader. Cells incubated with culture medium
were used as a control group. Each sample was assayed
in triplicate.
Colony-formation assays
Cell lines were trypsinized to generate a single-cell suspen-
sion, and 120 cells/well (MFE-296 cells) or 200 cells/well
(AN3CA cells) were seeded into 6-well plates. Dishes were
returned to the incubator for 14 days, and the colonies
were fixed with methanol for 30 min at room temperature
and then stained with 0.5% crystal violet for 1 h.
Cell migration and invasion assays
Cells were trypsinized, centrifuged, and resuspended in
serum-free medium. Cells were then plated at a density
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(for the invasion assay) in invasion chambers (8 μm pore
size; BD Biosciences, California, USA) with or without
matrigel coating for invasion and migration assays. Com-
plete medium (600 μl) was added to the lower chamber as
a chemoattractant. After incubation for 5 h (MFE-296) or
24 h (AN3CA) for the migration assay, or after incubation
for 24 h (MFE-296) or 48 h (AN3CA) for the invasion
assay, cells were fixed with 4% paraformaldehyde for 1 h.
Cells on the apical side of each insert were removed by
mechanical scraping. Cells that migrated to the basal side
of the membrane were stained with 0.5% crystal violet and
counted at 200× magnification. The migration and inva-
sion assays were repeated at least three times.
Xenograft tumor–formation assays
Female athymic mice of 4 weeks of age were obtained
from the Shanghai Experimental Animal Center of the
Chinese Academy of Science. Our animal research was
carried out in strict accordance with the recommendations
in the Guideline for the Care and Use of Laboratory
Animals of China. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the
Obstetrical and Gynecological Hospital affiliated Fudan
University (Permit Number: SYXK (hu) 2008–0064). All
efforts were made to minimize animal suffering.
To establish a nude mouse model bearing EC, unin-
fected MFE-296 cells (MFE-296), stable MFE-296 cells
infected with lentivirus carrying shFOXA1 (MFE-296/
shFOXA1) or vector alone (MFE-296/NC) were used.
All mice were randomly divided into three groups of
four mice. Each mouse was given a unilateral subcuta-
neous injection of 1 × 107 cells. Tumor measurement
began one week after injection and was conducted
weekly using digital calipers. The tumors were removed
and weighed after 42 days. Tumor volume was calcu-
lated as follows: tumor volume (cm3) = (the longest
diameter) × (the shortest diameter)2 × 0.5.
Immunohistochemical staining of mouse tumor samples
Tumor samples from xenografted mice were collected and
fixed according to routine procedures. Histological stain-
ing was then performed on the tissue sections of the
paraffin-embedded tumors using the streptavidin-biotin-
peroxidase method. Primary antibodies were as follows:
anti-FOXA1 (1:200; Abcam), anti-AR (1:50, Abcam), anti-
Notch1 (1:100; Epitomics,), anti-Hes1 (1:250; Epitomics),
anti-Ki67 (1:100; Boster, Wuhan, China), and anti-PCNA
(1:100; Boster). The sections were then counterstained
with hematoxylin and eosin (H&E).
Statistics
Measured data were assessed by unpaired Student’s
t-test or one-way ANOVA for multiple comparisons,and χ2 test for 2 × 2 tables was used to compare the cat-
egorical data. p < 0.05 was considered significant.
Results
Expression of FOXA1 and AR in endometrial tissues and
the clinicopathological significance in EC specimens
We assessed relative FOXA1 and AR levels in EC samples,
atypical hyperplasias, and normal endometrial tissue sam-
ples using immunohistochemistry. FOXA1 was higher in
atypical hyperplasias and even higher in EC compared
with normal endometrial tissues (p = 0.005) (Figure 1,
Additional file 1: Table S1). Notably, the expression of AR
was also significantly higher in EC (p = 0.033) (Figure 1,
Additional file 2: Table S2). The results also showed that
FOXA1 expression correlated positively with AR ex-
pression (p = 0.003) (Table 2). Correlation analysis be-
tween FOXA1 and pathological grade of EC showed
that FOXA1 expression was higher in G3 tumors (6/6)
compared with either G2 (17/22) or G1 (19/35) tumors
(p = 0.038) (Table 1). Significantly higher FOXA1 expres-
sion was also found in tumors that displayed a greater
depth of myometrial invasion (p = 0.035). Finally, our re-
sults also indicated that AR was much higher in G3 and
G2 tumors compared to G1 (p = 0.040) (Table 1). These
results suggested that FOXA1 expression, which corre-
lated with AR expression, had a connection with the de-
velopment of EC and risk-associated clinical features of
the disease.
FOXA1 affects AR expression in human EC cells
We used western blotting to examine FOXA1 and AR ex-
pression in EC cells. FOXA1 was upregulated in MFE-296
cells compared with KLE, HEC-1B, and AN3CA cells. Fur-
thermore, the AR level was also markedly higher in MFE-
296 cells than in the other three EC cell lines (Figure 2A).
We next manipulated FOXA1 expression and exam-
ined its influence on AR expression. AN3CA cells were
transiently transfected with a FOXA1 plasmid to over-
express FOXA1 (AN3CA/exFOXA1) or with control
vector (AN3CA/NC). Moreover, to knock down FOXA1
expression, MFE-296 cells were stably transfected with
FOXA1 shRNA (MFE-296/shFOXA1) or control vector
(MFE-296/NC) (Figure 2B). AR expression was then ana-
lyzed by qRT-PCR and western blotting, which showed that
the AR level was significantly enhanced by FOXA1 overex-
pression and reduced by FOXA1 depletion (Figure 2C–H).
Together, the data suggested that FOXA1 affected the AR
level in EC cells.
FOXA1 expression affects AR target gene expression in
human EC cells
We next examined whether the FOXA1 level impacted
the expression of AR target genes in EC cells. MFE-296
cells were hormone deprived and treated with vehicle or
Figure 1 Immunohistochemical staining of FOXA1 and AR in normal endometrium, atypical hyperplasias, and endometrial cancer.
FOXA1 and AR expression in normal endometrium, atypical hyperplasias and endometrial cancer. (Immunohistochemical staining, ×200).
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of AR target genes (XBP1, MYC, ZBTB16, and UHRF1)
[12] was evaluated by qRT-PCR. This analysis confirmed
that the expression of these four genes increased after
treatment with DHT. Furthermore, the dose-response
study (0–10−7 M DHT) and time-response study (0–48 h)
indicated that 10−7 M DHT and 24 h of incubation elic-
ited the strongest expression of AR and its target genes
(Figure 3A and 3B). These data confirmed that these
four genes were downstream of the AR-mediated tran-
scription in EC cells. To partially confirm the promoting
effect of DHT on AR-mediated transcription at the pro-
tein level, AR expression was examined by western blot-
ting; DHT acted as an agonist, whereas the addition of the
AR antagonist flutamide [21] reduced the DHT-enhanced
expression of AR in MFE-296 cells (Figure 3C).
To investigate whether FOXA1 influences AR-mediated
transcription, we transfected hormone-deprived EC cells
with shFOXA1, exFOXA1, or the appropriate negative
control vector and then treated them with vehicle or DHT
for 24 h. In MFE-296/NC cells, DHT caused a ≥10-foldTable 2 Immunohistochemical analysis of protein expression
Normal endometrium Atypical h
Negative Positive Negative
FOXA1 32 25 4
n 57 11
AR 30 27 5
n 57 11
*The relationship between FOXA1 and AR expression was assessed by χ2 test.increase in the expression of the four AR-regulated genes
compared with the MFE-296/NC cells treated with ve-
hicle. When FOXA1 expression was knocked down in
MFE-296 cells transfected with shFOXA1, however, the
expression of these genes was not as markedly increased,
and their expression decreased by 8- to 20-fold after treat-
ment with DHT (Figure 3D). Moreover, we found that the
increase in the expression of AR and AR-regulated genes
was remarkably greater by DHT in the AN3CA/exFOXA1
cells compared with the AN3CA/NC cells (Figure 3E).
Our findings indicated that FOXA1 expression globally
affected AR-mediated transcription, with all of the four
AR-regulated genes requiring FOXA1 for appropriate AR-
mediated regulation.
FOXA1 promotes AR target gene expression by
interaction with AR
FOXA1 can target a series of transcription factors repre-
senting anywhere from several to hundreds of genes. To
address whether the effects of FOXA1 on AR down-
stream targets are primarily through upregulating AR,in different endometrial tissues
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Figure 2 FOXA1 affects the expression of AR in human EC cells. A: FOXA1 and AR expression in the indicated EC cell lines as determined
were measured by western blotting (Left), and further quantified by densitometry of triplicate experiments (Right). β-actin was used as a loading
control. B: Stable transfection of MFE-296 cells with negative control vector (MFE-296-NC) or shFOXA1 (MFE-296-shFOXA1). By comparing the cells
in white light (the upper panels) with the cells in green fluorescence (the lower panels), the percentage of transfected/fluorescing cells was
estimated at >85%. Magnification, ×400. C: Quantification of FOXA1 mRNA by qRT-PCR in untransfected MFE-296 (MFE-296), MFE-296 transfected with
shRNA control plasmid (MFE-296/NC), and MFE-296 transfected with shFOXA1 (MFE-296/shFOXA1). D: Quantification of AR mRNA by qRT-PCR
in MFE-296, MFE-296/NC, and MFE-296/shFOXA1 cells. E: FOXA1 and AR expression in MFE-296, MFE-296/NC and MFE-296/shFOXA1 cells were
measured by western blotting (Left), and further quantified by densitometry of triplicate experiments (Right). F: Quantification of FOXA1 mRNA
by qRT-PCR in untransfected AN3CA (AN3CA), AN3CA transfected with control plasmid (AN3CA/NC), and AN3CA transfected with FOXA1
expression plasmid (AN3CA/exFOXA1). G: Quantification of AR mRNA by qRT-PCR in AN3CA, AN3CA/NC, and AN3CA/exFOXA1 cells. H: AR
and FOXA1 expression in AN3CA, AN3CA/NC and AN3CA/exFOXA1 cells were measured by western blotting (Left), and further quantified by
densitometry of triplicate experiments (Right). *p < 0.05, **p < 0.01, NS p > 0.05 compared with NC.
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ectly, we used untransfected MFE-296 cells (MFE-296)
and MFE-296 cells transfected with shFOXA1 (MFE-296/shFOXA1), NC (MFE-296/NC), or shFOXA1 to-
gether with exAR (MFE-296/shFOXA1 + exAR). qRT-
PCR and western blotting analysis confirmed that
Figure 3 (See legend on next page.)
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Figure 3 FOXA1 affects AR-mediated transcription. A: MFE-296 cells were treated with DHT (10−9 to 10−7 M) or vehicle (control) for 24 h. qRT-PCR
was used to assess the levels of AR, XBP1, MYC, ZBTB16, and UHRF1 mRNA. The levels of each mRNA are shown relative to the level expressed in the
vehicle sample. B: Quantification of AR, XBP1, MYC, ZBTB16, and UHRF1 mRNA by qRT-PCR in MFE-296 cells treated with 10−7 M DHT for 0–48 h.
C: Western blotting analysis of AR in MFE-296 cells treated with vehicle, 10−7 M DHT, or 10−7 M DHT plus 10−6 M flutamide (DHT + FLU) for 24 h. β-actin
was used as a loading control. D: MFE-296/NC and MFE-296/shFOXA1 cells were treated with 10−7 M DHT or vehicle for 24 h followed by qRT-PCR
analysis of AR, XBP1, MYC, ZBTB16, and UHRF1 mRNA. E: AN3CA/NC and AN3CA/exFOXA1 cells were treated with 10−7 M DHT or vehicle for 24 h
followed by qRT-PCR analysis of AR, XBP1, MYC, ZBTB16, and UHRF1 mRNA. F: Quantification of AR expression by qRT-PCR and western blotting in
untransfected MFE-296 cells (MFE-296) and MFE-296 cells transfected with NC (MFE-296/NC) or exAR (MFE-296/exAR). G: Expression of XBP1, MYC,
ZBTB16, and UHRF1 mRNA in untransfected MFE-296 cells and MFE-296 cells transfected with NC, shFOXA1, or shFOXA1 and exAR was measured by
qRT-PCR. H: Quantification of AR expression by qRT-PCR and western blotting in untransfected AN3CA cells (AN3CA) and AN3CA cells transfected with
NC (AN3CA/NC) or siAR (AN3CA/siAR). I: Expression of XBP1, MYC, ZBTB16, and UHRF1 mRNA in untransfected AN3CA cells and AN3CA cells transfected
with NC, exFOXA1, or exFOXA1 and siAR was measured by qRT-PCR. *p < 0.05, **p < 0.01, ***p < 0.001, NS p > 0.05.
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(Figure 3F). qRT-PCR verified that MFE-296/shFOXA1
cells exhibited substantial decreases in the four AR tar-
gets compared with MFE-296/NC cells (Figure 3G).
Furthermore, cotransfection with exAR rescued the inhib-
ited expression of the target genes caused by FOXA1
downregulation in MFE-296/shFOXA1 cells (Figure 3G).
In addition, we used untransfected AN3CA cells (AN3CA)
and AN3CA cells transfected with NC (AN3CA/NC), ex
FOXA1 (AN3CA/exFOXA1), or exFOXA1 together with
siAR (AN3CA/exFOXA1 + siAR). qRT-PCR and western
blotting analysis confirmed that transfection with siAR re-
sulted in silencing of AR (Figure 3H). Overexpression of
FOXA1 increased the expression of the four AR target
genes. Moreover, cotransfection with siAR partially re-
versed the FOXA1-induced overexpression (Figure 3I).
These results verified that AR downregulation attenuated
the effect of FOXA1 on AR-mediated transcription and
suggested that FOXA1 might promote AR downstream
targets at least in part through AR.
FOXA1 and AR are found in the same protein complex
To investigate whether FOXA1 affects AR-mediated tran-
scription through binding to AR, we performed co-immu-
noprecipitation experiments. We used nuclear lysates from
MFE-296 cells to conduct immunoprecipitation with
anti-FOXA1. FOXA1 co-immunoprecipitated with AR,
whereas immunoprecipitation with the isotype IgG con-
trol did not pull down AR or FOXA1 (Figure 4A), indi-
cating that FOXA1 interacted with AR in MFE-296
cells. We also performed the co-immunoprecipitation
experiment in AN3CA cells, which has low level of AR.
As shown in Figure 4B, AR could be immunoprecipi-
tated by anti-FOXA1 in the presence of DHT but not in
its absence. This result indicated that FOXA1 and AR
interacted physically. It is likely that FOXA1 affects
AR-mediated transcription via binding with AR.
We further examined whether FOXA1 and AR could
bind to the five putative FOXA1-AR binding regions,
including the promoter and enhancer regions upstream
of the TSS (transcription start sites) of AR target genessuch as MYC (Figure 4C). Our ChIP assays showed that
both FOXA1 and AR could bind to all the five putative
FOXA1-AR-binding regions in MFE-296 cells. More-
over, both FOXA1 and AR bound most greatly to the
Enh-1 (enhancer 1) region among the five binding
regions (Figure 4D). Our ChIP data together with our co-
immunoprecipitation data suggested that FOXA1 forming
protein complex with AR might bind to FOXA1-AR over-
lapping binding regions upstream of MYC, leading to
MYC activation in EC cells.
AR is required for FOXA1-enhanced Notch pathway
activation of EC cells
Pathway analysis in liver cancer shows that FOXA1/AR
dual target genes are most involved in the cellular
growth/proliferation pathway [22]. Notch pathway acti-
vation appears to affect proliferation in many cancers. In
EC, the Notch pathway has also been shown to be in-
volved in cell proliferation [17]. Thus, we considered
that the interaction between FOXA1 and AR might be
related with the Notch pathway. We used western blot
analysis to assess the levels of Notch1 and the Notch
pathway target protein, Hes1, in MFE-296/shFOXA1
and AN3CA/exFOXA1 cells after exAR or siAR cotrans-
fection, respectively. Cotransfection with exAR rescued
the decreased expression of Notch1 and Hes1 caused
by FOXA1 downregulation in MFE-296/shFOXA1 cells
(Figure 4E). Furthermore, cotransfection with siAR at-
tenuated the increased expression of Notch1 and Hes1
caused by upregulation of FOXA1 in AN3CA/exFOXA1
cells (Figure 4F). These results suggested that the effects
of FOXA1 on Notch pathway activation were mediated by
AR. In order to determine whether AR was required for
FOXA1-enhanced Notch pathway activation, we over-
expressed AR expression in AN3CA cells, which has low
level of AR. We assessed the levels of Notch1 and Hes1 in
untransfected AN3CA cells (AN3CA) as well as AN3CA
cells transfected with NC (AN3CA/NC), exAR (AN3CA/
exAR), or exAR together with siFOXA1 (AN3CA/exAR +
siFOXA1). AN3CA/exAR cells exhibited a substantial in-
crease in AR expression as compared to AN3CA/NC cells,
Figure 4 FOXA1 affects AR-mediated transcription via binding with AR and activates the Notch pathway. A: Co-immunoprecipitation (IP)
of FOXA1 with AR in MFE-296 cells. WB: western blotting. B: Co-immunoprecipitation of FOXA1 with AR in AN3CA cells treated with 10−7 M DHT
or vehicle. C: Schematic representation of the MYC locus. FOXA1-binding sites and AR-binding sites upstream of the TSS of MYC were predicted
by ChIP-seq analysis. ChIP-PCR assays were performed using anti-FOXA1 antibody or anti-AR antibody. Pro: promoter region; Enh-1: enhancer 1
region; End-2: enhancer 2 region; TSS: transcription starting sites. D: Immunoprecipitated DNA fragments in ChIP-PCR assays were examined by qRT-PCR.
Each sample was assayed in triplicate in each of three independent experiments. IgG was used as negative control. Primers were designed specifically
for the promoter region (Pro), the enhancer 1 region (Enh-1), and the three putative FOXA1-AR binding sites within enhancer 2 region (Enh-2a, Enh-2b,
and Enh-2c) according to the study [19]. E: Protein levels of FOXA1, AR, Notch1, and Hes1 in untransfected MFE-296 cells (MFE-296) and MFE-296 cells
transfected with NC (MFE-296/NC), shFOXA1 (MFE-296/shFOXA1), or shFOXA1 and exAR (MFE-296/shFOXA1 + exAR) were measured by western blotting
(Right), and further quantified by densitometry of triplicate experiments (Left). F: Protein levels of FOXA1, AR, Notch1, and Hes1 in untransfected AN3CA
cells (AN3CA) and AN3CA cells transfected with NC (AN3CA/NC) , exFOXA1 (AN3CA/exFOXA1), or exFOXA1 and siAR (AN3CA/exFOXA1 + siAR) were
measured by western blotting (Right), and further quantified by densitometry of triplicate experiments (Left). β-actin was used as a loading control.
*p < 0.05, **p < 0.01 and NS p > 0.05.
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(Additional file 3: Figure S1). Furthermore, cotransfection
with siFOXA1 did not rescue the activation of Notch1 and
Hes1 caused by AR upregulation in AN3CA/exAR cells(Additional file 3: Figure S1). These results suggested a
mechanism, where AR might be a necessary medium in
FOXA1-enhanced Notch pathway activation in AN3CA
cells.
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To examine the role of FOXA1 in EC cell proliferation,
we assessed the effect of FOXA1 in colony-forming and
MTT assays. In the colony-forming assay, MFE-296 cellFigure 5 FOXA1 promotes proliferation of human EC cells by affectin
transfected with NC or shFOXA1 was assessed by the colony-forming as
triplicate experiments (Right). B: Proliferation in AN3CA cells transfected
(Left) and further quantified in the number of colonies of triplicate expe
MFE-296 cells transfected with NC or shFOXA1. D: Assessment of proliferation
Colony-formation assay of untransfected MFE-296 cells (WT) and MFE-296
Graphical representation of the fold change in the number of colonies in
with NC (MFE-296/NC), shFOXA1 (MFE-296/shFOXA1), or shFOXA1 and ex
NC, MFE-296/shFOXA1, or MFE-296/shFOXA1 + exAR cells was assessed by
72 h. *p < 0.05, **p < 0.01, ***p < 0.001 and NS p > 0.05.transfected with shFOXA1 showed significantly decreased
colony-forming ability when compared with MFE-296
cells transfected with NC (Figure 5A). Moreover, upre-
gualtion of FOXA1 in AN3CA cells showed increasedg AR-mediated transcription. A: Proliferation in MFE-296 cells
say (Left) and further quantified in the number of colonies of
with NC or exFOXA1 was assessed by the colony-forming assay
riments (Right). C: Assessment of proliferation by the MTT assay in
by the MTT assay in AN3CA cells transfected with NC or exFOXA1. E: Left:
cells transfected with NC, shFOXA1, or shFOXA1 and exAR. Right:
untransfected MFE-296 cells (MFE-296) and MFE-296 cells transfected
AR (MFE-296/shFOXA1 + exAR). F: Proliferation of MFE-296, MFE-296/
MTT assay. The right panel reiterates the data in the left panel at
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In the MTT assay, downregulation of FOXA1 in MFE-296
cells resulted in poor cell viability (Figure 5C), and upregu-
lation of FOXA1 in AN3CA cells caused increased cell
viability (Figure 5D). These data indicated that FOXA1
promoted cell proliferation.
AR is required for FOXA1-enhanced proliferation of EC
cells
To directly address whether the effects of FOXA1 in
promoting EC cell proliferation can be attributed to its
activation of AR, a rescue experiment in MFE-296 cells
was performed. In the colony-forming assay, cotransfec-
tion with exAR rescued the decreased rate of cell growth
caused by FOXA1 downregulation in shFOXA1 cells
(Figure 5E). The MTT assay also showed that cotransfec-
tion with exAR rescued the inhibition of cell viability
caused by FOXA1 downregulation in shFOXA1 cells
(Figure 5F). The similarity of results from the colony-
forming and MTT assays suggested that the effects of
FOXA1 in mediating cell proliferation of EC cells were
mediated through AR.
AR is not required for FOXA1-enhanced migration and
invasion of EC cells
Our immunohistochemistry results revealed that pa-
tients with myometrial invasion displayed higher FOXA1
expression. With this observation in mind, we hypothe-
sized that functional expression of FOXA1 might induce
tumor metastasis in EC. To explore the role of FOXA1
in the regulation of metastatic function and to determine
whether AR is involved in FOXA1-mediated regulation
of metastatic function, we examined the migration and
invasion ability of MFE-296/shFOXA1 and AN3CA/
exFOXA1 cells after exAR or siAR cotransfection using
transwell migration and invasion assays. MFE-296/
shFOXA1 cells displayed a decreased rate of migration
compared to MFE-296/NC cells (Figure 6A). However,
cotransfection of MFE-296/shFOXA1 cells with exAR
(MFE-296/shFOXA1 + exAR) did not rescue the migration
to the levels observed in MFE-296/NC or untransfected
cells (MFE-296) (Figure 6A). Furthermore, AN3CA/
exFOXA1 cells exhibited a high migration rate as com-
pared with AN3CA/NC cells, but cotransfection with siAR
(AN3CA/exFOXA1 + siAR) did not significantly attenuate
the migration rate (Figure 6B).
Consistent with these findings, the invasion rate was
significantly reduced in MFE-296/shFOXA1 cells, but
the reduction was not reversed upon transfection with
exAR (Figure 6C). Likewise, the invasion rate was en-
hanced in AN3CA/exFOXA1 cells, but this enhance-
ment was not attenuated upon transfection with siAR
(Figure 6D). These results demonstrated a functional
role for FOXA1 in mediating migration and invasion inEC cells and suggested a mechanism (distinct from that
for EC cell proliferation) by which AR might not con-
tribute to FOXA1-mediated metastasis of EC.
Oncogenic role of FOXA1 in a tumor xenograft model
Tumors generated by subcutaneous implantation of
MFE-296 cells were used to evaluate the effect of
FOXA1 on proliferation in a mouse tumor xenograft
model. We measured tumor volumes in xenografted
mice over a 6-week period following injection of
untransfected MFE-296 (MFE-296), stably transfected
with shFOXA1 (MFE-296/shFOXA1) or NC (MFE-296/
NC). These measurements indicated that tumors in the
MFE-296/shFOXA1 group grew significantly slower than
those in the MFE-296/NC group and the MFE-296
group (Figure 7A). Six weeks after injection, tumors
were removed from the mice (Figure 7C). The final
mean weight and volume of tumors in the MFE-296/
shFOXA1 group were significantly lower than those in
the MFE-296/NC group (p < 0.05, Figure 7B and 7C).
Tumor tissues were then embedded in paraffin, stained
with hematoxylin and eosin (H&E), and immunohisto-
chemically stained with antibodies against FOXA1, AR,
Notch1, Hes1, Ki67, or PCNA. Lower FOXA1 expres-
sion in the MFE-296/shFOXA1 group also led to re-
duced staining for AR, indicating that FOXA1 also
affected AR expression in vivo, in accordance with the
results in vitro. As expected, the MFE-296/shFOXA1
group had significantly lower levels of Notch1 and Hes1
(Figure 7D), thus verifying the role of FOXA1 as a posi-
tive regulator of the Notch pathway in vivo. Further-
more, to determine the proliferative ability of MFE-296
cells, we performed immunohistochemical staining of
Ki67 and PCNA, which are expressed as proliferation in-
dices. The observed lower expression of Ki67 and PCNA
in the MFE-296/shFOXA1 group was consistent with
the smaller tumor volumes in the mouse tumor xeno-
graft model (Figure 7D).
Discussion
Over the past decade, FOXA1 expression has been
examined in several human cancers, and oncogenic
and tumor-suppressive roles have been proposed for
FOXA1 depending on the cancer type and, in some
cases, the subtype. In acute myelocytic leukemia,
esophageal squamous cell carcinomas, lung adenocar-
cinomas, thyroid carcinoma, prostate cancer, and AR-
positive molecular apocrine breast cancer [12,23-25],
FOXA1 acts as an oncogene. However, in hepatocel-
lular carcinoma, pancreatic, and estrogen receptor
(ER)-positive breast cancer, FOXA1 has been reported
to have a tumor-suppressive function [26-28]. On one
hand, FOXA1 acts as a tumor oncogene. In oeso-
phageal squamous cell carcinoma, FOXA1 expression
Figure 6 FOXA1 induces migration and invasion in EC cells. A: Cell migration of MFE-296, MFE-296/NC, MFE-296/shFOXA1 and MFE-296/
shFOXA1 + exAR cells was assessed by the transwell migration analysis (Left). The mean ± SD number of migrated cells of three independent
experiments was showed in the right panel. The abbreviation “HPF” on the y axis means one high power field. B: Cell migration of AN3CA,
AN3CA/NC, AN3CA/exFOXA1 and AN3CA/exFOXA1 + siAR cells were subjected to transwell migration analysis (Left). The mean ± SD number of
migrated cells of three independent experiments was showed in the right panel. C: Cell invasion of MFE-296, MFE-296/NC, MFE-296/shFOXA1 and
MFE-296/shFOXA1 + exAR cells was assessed by the transwell invasion analysis (Left). The mean ± SD number of invased cells of three independent
experiments was shown in the right panel. D: Cell invasion of AN3CA, AN3CA/NC, AN3CA/exFOXA1 and AN3CA/exFOXA1 + siAR cells by three
independent experiments were subjected to transwell invasion analysis (Left). The mean ± SD number of invased cells of three independent
experiments was showed in the right panel. (Magnification, 200×). *p < 0.05, **p < 0.01, ***p < 0.001, and NS p > 0.05.
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histochemical specimens and FOXA1 expression in-
hibition decreases cellular invasion and migration [29].
Also, FOXA1 is over-expressed in aggressive thyroid
cancers (ATC) and involved in cell cycle progression
via down-regulation of p27Kip1 in an ATC cell line [30].
On the other hand, FOXA1 has been reported to act as
a tumor suppressor. It has been reported that FOXA1
positively regulates miRNA-122, which is correlated
with favourable prognosis in human hepatocellular car-
cinoma [26]. In addition, FOXA1 acts as an important
antagonist of the epithelial-to-mesenchymal transition
(EMT) in pancreatic ductal adenocarcinoma through
its positive regulation of E-cadherin and maintenance
of the epithelial phenotype [27]. It is critical to note
that the role of FOXA1, as a tumor oncogene or a
tumor suppressor gene, has been reported to vary in
prostate and breast cancers depending on multiple
cancer subtypes and states of hormone dependence or
independence [11,12,28].
A previous study has addressed the expression and func-
tion of FOXA1 in EC; immunohistochemical analysis by
Abe et al. indicated that FOXA1 was negatively associatedwith lymph node status in EC immunohistochemical spec-
imens in Japanese, and FOXA1 repressed proliferation
and migration in one type of EC cells (Ishikawa) [31].
However, our study found that the FOXA1 level in ECs
was significantly higher than that in atypical hyperplasia
and normal tissues (p < 0.05) in immunohistochemical
specimens and that FOXA1 promoted tumor cell prolifer-
ation in EC, which differs from the previous results. The
difference might be attributed to the immunohistochemi-
cal samples in different countries used. Alternatively, the
cancer subtype may affect the results: the function of
FOXA1 as a tumor suppressor in the Abe et al. study was
investigated in the Ishikawa cell line, which is ER-positive
[32], whereas we used MFE-296 (high levels of FOXA1
and AR) and AN3CA (low levels of FOXA1 and AR),
which are both ER-negative cell lines [33,34]. This idea
consists with breast cancer studies that have shown that
FOXA1 functions as a tumor suppressor in ER-positive
breast cancer cells (MCF-7) [28] but as a tumor activator
in ER-negative breast cancer cells (MDA-MB-453) [12].
Furthermore, this idea of the effects of forkhead family
members depending on ER expression is also consistent
with the study that have shown the Forkhead box class o
Figure 7 Tumorigenicity assay in nude mice. A: The growth rates of tumors formed from untransfected MFE-296 cells (MFE-296) and MFE-296
cells transfected with NC (MFE-296/NC) or shFOXA1 (MFE-296/shFOXA1). After injection, tumor volumes were calculated every seven days. B and
C: Six weeks after injection of MFE-296, MFE-296-NC, and MFE-296-shFOXA1 cells, tumors were removed, and the tumor weights and volumes
were determined. Arithmetic means and SD are shown. D: Staining with hematoxylin and eosin (H&E) or immunohistochemical staining for
FOXA1, AR, Notch1, Hes1, Ki67, and PCNA in mouse tumor tissues (immunohistochemical staining, 200×). *p < 0.05 compared with the NC group.
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motility and invasiveness of ER-positive breast cancer cells
but inducing effects on motility and invasiveness of ER-
negative breast cancer cells [35]. More comprehensive
studies covering several EC cell lines in different cancer
subtypes will be necessary to define the role of FOXA1 in
EC development.
Most researches on hormone receptors in EC have fo-
cused on ER and progesterone receptor (PR). However,
the expression of AR in the human normal endomet-
rium and its disorders is not well understood. Though
higher serum androgen levels have been certified to exist
in the utero-ovarian vein blood samples from women
with EC [36], the details of AR expression and its actions
in EC are a topic of dispute. Longer CAG repeats in AR
promote carcinogenesis of uterine endometrial cells [37].
Androgens and AR may be involved in endometrial cell
proliferation by regulating the expression of insulin growthfactor I (IGF-I) in the uterus [38]. Our results suggest that
AR expression is significantly higher in EC than in normal
endometrium and that AR activated by FOXA1 might
promote the Notch pathway, which may be another mech-
anism involving AR in EC.
Most FOXA1 studies have focused on its role as a
pioneer factor that binds to DNA packaged in chromatin
and opens the chromatin for binding of additional tran-
scription factors including AR [39,40]. According to our
results from qRT-PCR and western blotting, FOXA1
regulates AR target genes by up-regulation of AR ex-
pression. Interestingly, our co-immunoprecipitation re-
sults (Figure 4A and 4B) showed that FOXA1 interacted
with AR at the protein level. Apart from that, our ChIP-
PCR results suggested that FOXA1 and AR were directly
bound to the same regions upstream of MYC (Figure 4C
and 4D). Based on the above results, we suggest that
FOXA1 may also directly regulate AR target genes
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garding an interaction between AR and FOXA1 may be
related to the finding that the AR and FOXA1 binding
sites are adjacent on multiple promoters of AR target
genes in prostatic cells [9,41]. Thus, FOXA1 may regu-
late the AR target genes through at least two means: AR
over-expression or physical interaction with AR in order
to induce easy AR accessibility to binding to its target
genes. MYC is an immediate early response gene down-
stream from AR pathway and is tightly regulated
through AR cis-regulatory elements identified within its
proximal promoters and distal enhancer regions [19],
which is consistent with our ChIP-PCR results (Figure 4C
and 4D). Interestingly, we showed that FOXA1 and AR
more evidently bound to the MYC enhancer regions
as compared to MYC promoter regions. These results
could be attributed to other co-regulators involved in
this binding process. Since TCF7L2, a protein mediating
DNA looping for long-distance interactions of distal en-
hancers and proximal promoters, physically interacts
with FOXA1 and AR and mediates the transcription of
MYC in breast cancer [19], future investigation will be
needed to clarify which co-regulators are involved in
FOXA1/AR binding to the enhancer regions upstream
of MYC in EC cells.
Although the underlying mechanisms governing the
FOXA1-AR correlation in tumor progression are not
fully understood, a pathway analysis showed that 187
FOXA1/AR dual target genes were involved in the cellu-
lar growth/proliferation pathway in liver cancer [22].
The Notch pathway is implicated in the development of
various cancers, and the Notch pathway blockade ap-
pears to affect cell proliferation in multiple types of can-
cers. Notch pathway inhibition in breast cancer cells
induces cell cycle arrest and apoptosis [42]. Similarly,
downregulation of Notch1 contributes to cell growth in-
hibition in pancreatic cancer [43]. Our results suggest
that downregulation of AR attenuated FOXA1-induced up-
regulation of the Notch pathway in EC cells. These findings
indicate that FOXA1 might promote AR-mediated tran-
scription and ultimately activate the Notch pathway. Here,
we describe, for the first time, the association between
FOXA1 expression and the Notch pathway in cancer.
The specific mechanism of cell proliferation in EC re-
ported so far has been limited, although several classical
transcription factors related to proliferation have been
identified, including cyclin D1, p53, IGFBP-1, PTEN, and
p27Kip1 [44-48]. In this study, we suggest that FOXA1 pro-
motes cell proliferation in EC by interaction with AR, pos-
sibly via the Notch pathway, which may be a newly
identified regulatory mechanism of cell proliferation in EC.
We further investigated the effects of FOXA1 and AR
on migration and invasion of EC cells, and found that
neutralization of AR activity did not inhibit FOXA1-enhanced cancer cell migration or invasion. These obser-
vations indicate that the promoting effect of FOXA1 on
migration and invasion is not dependent on AR. Our
findings in migration and invasion assays are consistent
with our findings in immunohistochemical staining,
which showed that higher expression of FOXA1 but not
AR is found in tumors that displayed a greater depth of
myometrial invasion. These results suggest that AR is
not the only downstream target of FOXA1 in EC. Future
studies will be necessary to define which transcription
factors or pathways are involved in FOXA1-enhanced
cell migration and invasion in EC.
The traditional endocrine treatment (mainly target-
ing ER and PR) is ineffective in most ER-negative and
PR-negative ECs, and even in some ER-positive and
PR-positive ECs [49]. In our investigation, 9 of the15
ER-negative EC cases (60.0%) and 41 of the 61 ER-
positive EC cases (67.2%) were AR positive, and the
majority of ECs were also FOXA1 positive (Table 1).
Thus, AR and FOXA1 might be alternative targets in
ECs insensitive to traditional endocrine treatment or
could be targets for adjuvant treatment following sur-
gery and traditional endocrine treatment. There has
been speculation about the use of anti-androgens for
the treatment of ECs [50]; this hypothesis warrants
clinical investigation in light of our findings.Conclusions
In summary, our results suggest a new mechanism for
the development of EC, in which FOXA1 promotes
tumor cell proliferation through AR and activates the
Notch pathway by influencing AR expression. The newly
identified FOXA1-AR interaction will help further eluci-
date the molecular mechanisms underlying EC progres-
sion and suggests that FOXA1 and AR are potential
targets for EC treatment.Additional files
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